Descrizione del progetto
Migliorare il trattamento e la gestione del cancro al fegato
Il cancro al fegato, che colpisce ogni anno circa 1 milione di persone in tutto il mondo, rappresenta una sfida per la salute, con l’Europa che registra ogni anno circa 90 000 nuovi casi. È la terza causa di mortalità per cancro a livello globale. Il carcinoma epatocellulare e l’epatoblastoma, in particolare, presentano ostacoli complessi al trattamento a causa delle loro caratteristiche poco conosciute. In questo contesto, il progetto THRIVE, finanziato dall’UE, affronta questa crisi con un approccio multidisciplinare che riunisce 13 partner in otto paesi. Utilizzando tecnologie all’avanguardia come RNASeq a singola cellula e l’intelligenza artificiale, THRIVE mira a comprendere le popolazioni a rischio, la biologia dei tumori e la resistenza ai trattamenti. Analizzando 6 700 campioni provenienti da 15 coorti di pazienti, THRIVE cerca di sviluppare biomarcatori per le terapie attuali e nuovi trattamenti accessibili.
Obiettivo
"Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma (HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%) with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease progression after surgical intervention and adjuvant chemotherapy.
THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from 8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors (i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples).
THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such as the UNCAN.eu platform, and by influencing policymakers and health professionals.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)""."
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.2.1 - Health Main Programme
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
08036 Barcelona
Spagna